Literature DB >> 12584367

Circulating endothelial progenitor cells, vascular function, and cardiovascular risk.

Jonathan M Hill1, Gloria Zalos, Julian P J Halcox, William H Schenke, Myron A Waclawiw, Arshed A Quyyumi, Toren Finkel.   

Abstract

BACKGROUND: Cardiovascular risk factors contribute to atherogenesis by inducing endothelial-cell injury and dysfunction. We hypothesized that endothelial progenitor cells derived from bone marrow have a role in ongoing endothelial repair and that impaired mobilization or depletion of these cells contributes to endothelial dysfunction and cardiovascular disease progression.
METHODS: We measured the number of colony-forming units of endothelial progenitor cells in peripheral-blood samples from 45 men (mean [+/-SE] age, 50+/-2 years). The subjects had various degrees of cardiovascular risk but no history of cardiovascular disease. Endothelium-dependent and endothelium-independent function was assessed by high-resolution ultrasonography of the brachial artery.
RESULTS: We observed a strong correlation between the number of circulating endothelial progenitor cells and the subjects' combined Framingham risk factor score (r=-0.47, P=0.001). Measurement of flow-mediated brachial-artery reactivity also revealed a significant relation between endothelial function and the number of progenitor cells (r=0.59, P<0.001). Indeed, the levels of circulating endothelial progenitor cells were a better predictor of vascular reactivity than was the presence or absence of conventional risk factors. In addition, endothelial progenitor cells from subjects at high risk for cardiovascular events had higher rates of in vitro senescence than cells from subjects at low risk.
CONCLUSIONS: In healthy men, levels of endothelial progenitor cells may be a surrogate biologic marker for vascular function and cumulative cardiovascular risk. These findings suggest that endothelial injury in the absence of sufficient circulating progenitor cells may affect the progression of cardiovascular disease. Copyright 2003 Massachusetts Medical Society

Entities:  

Mesh:

Year:  2003        PMID: 12584367     DOI: 10.1056/NEJMoa022287

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  965 in total

1.  Human umbilical cord blood endothelial progenitor cells decrease vein graft neointimal hyperplasia in SCID mice.

Authors:  Shoukang Zhu; Anuj Malhotra; Lisheng Zhang; Shanming Deng; Taifang Zhang; Neil J Freedman; Robert Storms; Karsten Peppel; Pascal J Goldschmidt-Clermont; Chunming Dong
Journal:  Atherosclerosis       Date:  2010-04-21       Impact factor: 5.162

2.  Granulocyte colony-stimulating factor (G-CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration therapy.

Authors:  O Tura; J Crawford; G R Barclay; K Samuel; P W F Hadoke; H Roddie; J Davies; M L Turner
Journal:  J Thromb Haemost       Date:  2010-05-04       Impact factor: 5.824

3.  The biocompatibility of titanium cardiovascular devices seeded with autologous blood-derived endothelial progenitor cells: EPC-seeded antithrombotic Ti implants.

Authors:  Hardean E Achneck; Ryan M Jamiolkowski; Alexandra E Jantzen; Justin M Haseltine; Whitney O Lane; Jessica K Huang; Lauren J Galinat; Michael J Serpe; Fu-Hsiung Lin; Madison Li; Amar Parikh; Liqiao Ma; Tao Chen; Bantayehu Sileshi; Carmelo A Milano; Charles S Wallace; Thomas V Stabler; Jason D Allen; George A Truskey; Jeffrey H Lawson
Journal:  Biomaterials       Date:  2010-11-05       Impact factor: 12.479

4.  Loss of endothelial-ARNT in adult mice contributes to dampened circulating proangiogenic cells and delayed wound healing.

Authors:  Yu Han; Jiayi Tao; Alla Gomer; Diana L Ramirez-Bergeron
Journal:  Vasc Med       Date:  2014-11-14       Impact factor: 3.239

Review 5.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

6.  Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells.

Authors:  Qi Liu; Yutao Xi; Toya Terry; Shui-Ping So; Anita Mohite; Jia Zhang; Geru Wu; Xiaobing Liu; Jie Cheng; Ke-He Ruan; James T Willerson; Richard A F Dixon
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

7.  Novel measurements of mammary stem cells in human umbilical cord blood as prospective predictors of breast cancer susceptibility in later life.

Authors:  L Qiu; H P Low; C-I Chang; W C Strohsnitter; M Anderson; K Edmiston; H-O Adami; A Ekbom; P Hall; P Lagiou; D Trichopoulos; C-C Hsieh
Journal:  Ann Oncol       Date:  2011-04-22       Impact factor: 32.976

8.  Endothelial dysfunction in the smokers can be improved with oral cilostazol treatment.

Authors:  Kyu Seop Kim; Hyung Seo Park; Il Soon Jung; Jae-Hyeong Park; Kye Taek Ahn; Seon-Ah Jin; Yong Kyu Park; Jun Hyung Kim; Jae-Hwan Lee; Si Wan Choi; Jin-Ok Jeong; In-Whan Seong
Journal:  J Cardiovasc Ultrasound       Date:  2011-03-31

9.  The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells.

Authors:  Emerson E Sharpe; Amylynn A Teleron; Bin Li; James Price; Mark S Sands; Kathy Alford; Pampee P Young
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

10.  Proangiogenic cell colonies grown in vitro from human peripheral blood mononuclear cells.

Authors:  Kreton Mavromatis; Diane J Sutcliffe; Giji Joseph; R Wayne Alexander; Edmund K Waller; Arshed A Quyyumi; W Robert Taylor
Journal:  J Biomol Screen       Date:  2012-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.